We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Regulator Missing in Prostate Cancer

By Biotechdaily staff writers
Posted on 26 Jun 2003
Researchers have found that the angiogenesis inhibitor, pigment epithelium–derived factor (PEDF), is a key inhibitor of blood vessel development and epithelial tissue growth in mouse prostate and pancreas. More...


Investigators from Northwestern University (Evanston, IL, USA) found that mice lacking PEDF developed an enlarged prostate, resembling human benign prostatic hyperplasia. In a study published in the June 2003 issue of Nature Medicine, they report that PEDF was present in healthy prostate tissue and normal prostate cells, but that little or no PEDF was present in prostate cancer tissue or in isolated prostate cancer cells grown in tissue culture. They found that adding purified PEDF to cultured prostate cancer cells triggered an increased rate of prostate cancer cell death. This effect was enhanced when the cells were deprived of oxygen.

Androgen ablation therapy is an important aspect of prostate cancer treatment. The current study found that this treatment activated PEDF in the cancerous tissue, closed down synthesis of new blood vessels, and led to death of tumor cells.




Related Links:
Northwestern University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Manual Pipetting Aid
Pipette Controllers macro
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.